Potential indications and combinations of systemic TLR4 agonist are likely to be very diverse as exemplified by our results in colorectal and lymphoma models, both as monotherapy and in combination with a therapeutic monoclonal antibody like rituximab. Here, TLR4 is linked to lymphoma.